You are here

  • Home
  • Archive
  • Volume 91, Issue 8
  • N-acetylcysteine for prevention of radiocontrast induced nephrotoxicity: the importance of dose and route of administration

Article Text

Article menu
Download PDFPDF
Editorial
N-acetylcysteine for prevention of radiocontrast induced nephrotoxicity: the importance of dose and route of administration
  1. S J Shalansky1,*,
  2. G E Pate2,
  3. A Levin3,
  4. J G Webb2
  1. 1Pharmacy Department, St Paul’s Hospital, Vancouver, BC, Canada
  2. 2Division of Cardiology, St Paul’s Hospital, Vancouver
  3. 3Division of Nephrology, St Paul’s Hospital, Vancouver
  1. Correspondence to:
    Stephen Shalansky
    PharmD, FCSHP, Pharmacy Department, St Paul’s Hospital, 1081 Burrard Street, Vancouver, BC, Canada V6Z 1Y6; sshalanskyprovidencehealth.bc.ca

Abstract

Dose and route of administration of N-acetylcysteine are key factors to consider when evaluating whether this agent is effective in preventing radiocontrast induced nephropathy

  • NAC, N-acetylcysteine
  • RCIN, radiocontrast induced nephropathy
  • N-acetylcysteine
  • contrast nephrotoxicity
  • route of administration

https://doi.org/10.1136/hrt.2004.053579

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • ↵* Also at the Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada

    • Competing interest statement: There are no grants, business interests, or consultancies that could lead to a conflict of interest.

    Linked Articles

    • Miscellanea
      Web Top 10
      BMJ Publishing Group Ltd and British Cardiovascular Society
      Heart 2005; 91 1337-1337 Published Online First: 14 Sep 2005.